Standard immunization currently averts an estimated two to three million deaths every year in all age group. Innovative technology solutions that help to ensure vaccine effectiveness, efficiency, safety, and storage are enabling immunization programs to save even more lives and the current conference focus on Cancer Immunology, Molecular Immunology, and Clinical Immunology. Without vaccines as well as safe vaccine distribution and delivery practices, deaths, particularly in children, would increase dramatically. The impact of vaccines goes far beyond saving lives and recovering the health of HIV-infected people and Hepatitis. Vaccination is in every sense an investment, with wider benefits that accrue across a lifetime. Enhancing financial security and reducing risk, eradicating infection through vaccination may lead to increased investment and improved political and economic stability and healthy people in the world.
Vaccines 2017 brings all the top researchers, innovators and experts in the field with an opportunity to interact and discuss the latest technologies and challenges in Vaccination. There is nothing more powerful than when this elite community comes together to share ideas, research matters, and hope.
And also the organizing committee is confident that participants will benefit from the high-value scientific program and welcome all the researchers and experts to join us for these 3 days of stimulating discussions, knowledge sharing.
Vaccines 2017 conference organized at Dubai. It is a most populous city and business hub of the Middle East. Dubai is a center of international trading and tourism and as the leading conference and exhibition venue in this part of the world.
Market Analysis of Vaccines:
The global vaccines market is expected to reach $57,885.4 million by 2019 from $33,140.6 million in 2014, at a CAGR of 11.8% from 2014 to 2019.
The report segments this market on the basis of type, technology, disease indication, and end user. Among various end users, the pediatrics segment is expected to account for the largest share of the market and is expected to grow at the highest CAGR from 2014 to 2019. Growth in vaccine segment can be attributed to the rising prevalence of diseases and the increasing number of initiatives taken by government organizations for vaccination programs.
Based on geography, the global vaccines market is segmented into Europe, North America, Asia, and Rest of the World (RoW). North America is expected to account for the huge share of the market during the forecast period. Growth of this market is driven by factors such as increasing government support for vaccine development, rising company investments for vaccine research, and high prevalence of diseases.
Key players in the Vaccine market
Astellas Pharma Inc. (Japan)
CSL Limited (Australia)
Emergent Bio Solutions, Inc. (U.S.)
GlaxoSmithKline, plc. (U.K.)
Johnson & Johnson (U.S.)
MedImmune, LLC (U.S.)
Merck & Co. (U.S.)
Pfizer, Inc. (U.S.)
Sanofi Pasteur (France)
Serum Institute of India Pvt. Ltd. (India)